Hawkes T R, Smith B E
Biochem J. 1984 Nov 1;223(3):783-92. doi: 10.1042/bj2230783.
The inactive MoFe protein (NifB-Kp1) of nitrogenase from nifB mutants of Klebsiella pneumoniae may be activated by addition of the iron-molybdenum cofactor (FeMoco) extracted from active MoFe protein (Kp1). However, when apparently saturated with FeMoco, our preparations of NifB-Kp1 yielded activated protein, Kp1-asm, with a specific activity that was at best only 40% of that expected. This was not due to degradation of Kp1-asm, NifB-Kp1 or FeMoco during the activation reaction. Nor could activation be enhanced by addition of other nif-gene products or other proteins. Whereas fully active Kp1 contains 2 FeMoco/molecule, apparent saturation of our NifB-Kp1 preparations required the binding of only 0.4-0.65 FeMoco/molecule. By using chromatography Kp1-asm could be largely resolved from NifB-Kp1 that had not been activated. However, we were unable to isolate fully active MoFe protein (i.e. Kp1-asm containing 2 FeMoco/molecule) from solutions of NifB-Kp1 activated with FeMoco. The maximum activity/ng-atom of total Mo obtained for our purified Kp1-asm was approximately half the maximum activity for FeMoco. Since all NifB-Kp1 preparations contained some Mo, we suggest that FeMoco activated only those NifB-Kp1 molecules already containing one atom of (non-FeMoco) Mo, thus forming Kp1-asm with 2 Mo but only 1 FeMoco/molecule. Kp1-asm was identical with normal Kp1 in terms of its Mr, stability, e.p.r. signals, pattern of substrate reductions, CO inhibition and ATP/2e ratio. In addition, for preparations of differing specific activity, there was a constant and identical relationship between the e.p.r. signal intensity (from FeMoco) and the activity of both Kp1 and Kp1-asm. Assuming the above hypothesis on the structure of Kp1-asm, these data demonstrate that the two FeMoco sites in wild-type Kp1 operate independently.
肺炎克雷伯菌nifB突变体固氮酶的无活性钼铁蛋白(NifB-Kp1)可通过添加从活性钼铁蛋白(Kp1)中提取的铁钼辅因子(FeMoco)而被激活。然而,当NifB-Kp1制剂明显被FeMoco饱和时,所产生的激活蛋白Kp1-asm的比活性最高仅为预期值的40%。这并非由于激活反应过程中Kp1-asm、NifB-Kp1或FeMoco的降解所致。添加其他nif基因产物或其他蛋白质也无法增强激活效果。完全活性的Kp1每个分子含有2个FeMoco,而我们的NifB-Kp1制剂的明显饱和仅需要每个分子结合0.4 - 0.65个FeMoco。通过色谱法,Kp1-asm可与未被激活的NifB-Kp1在很大程度上分离。然而,我们无法从用FeMoco激活的NifB-Kp1溶液中分离出完全活性的钼铁蛋白(即每个分子含有2个FeMoco的Kp1-asm)。我们纯化的Kp1-asm每纳克原子总钼获得的最大活性约为FeMoco最大活性的一半。由于所有NifB-Kp1制剂都含有一些钼,我们推测FeMoco仅激活那些已经含有一个(非FeMoco)钼原子的NifB-Kp1分子,从而形成每个分子含有2个钼但仅1个FeMoco的Kp1-asm。Kp1-asm在分子量、稳定性、电子顺磁共振信号、底物还原模式、CO抑制和ATP/2e比率方面与正常Kp1相同。此外,对于不同比活性的制剂,电子顺磁共振信号强度(来自FeMoco)与Kp1和Kp1-asm的活性之间存在恒定且相同的关系。假设上述关于Kp1-asm结构的假设成立,这些数据表明野生型Kp1中的两个FeMoco位点独立发挥作用。